User profiles for Roger Bedimo

Roger Bedimo

Professor of Medicine, University of Texas Southwestern Medical Center
Verified email at utsouthwestern.edu
Cited by 6148

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel

RT Gandhi, R Bedimo, JF Hoy, RJ Landovitz, DM Smith… - Jama, 2023 - jamanetwork.com
Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new data, to …

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

R Bedimo, NM Maalouf, S Zhang, H Drechsler, P Tebas - Aids, 2012 - journals.lww.com
Background: Whereas tenofovir (TDF) exposure has been associated with decreased bone
density, it remains unclear whether it is associated with increased risk of osteoporotic …

Non-HACEK gram-negative bacillus endocarditis

…, D Iarussi, J Klein, C Chirouze, R Bedimo… - Annals of internal …, 2007 - acpjournals.org
Background: Infective endocarditis caused by non-HACEK (species other than Haemophilus
species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella …

Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results …

…, RP Tracy, CL Gibert, D Rimland, RJ Bedimo… - JAMA …, 2017 - jamanetwork.com
Importance With improved survival, heart failure (HF) has become a major complication for
individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends …

Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression

RJ Bedimo, KA McGinnis, M Dunlap… - JAIDS Journal of …, 2009 - journals.lww.com
Background: The incidence of non-AIDS-defining malignancies (non-ADMs) is reported as
unchanged or increasing in the highly active antiretroviral therapy era. Whether incidence of …

A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive …

…, M Gareca, F Queiroz-Telles, RJ Bedimo… - Clinical infectious …, 2009 - academic.oup.com
Background . The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose
on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but …

HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction

…, DA Leaf, M Budoff, D Rimland, R Bedimo… - JAIDS Journal of …, 2015 - journals.lww.com
Background: Traditional cardiovascular disease risk factors (CVDRFs) increase the risk of
acute myocardial infarction (AMI) among HIV-infected (HIV+) participants. We assessed the …

Escherichia coli Sequence Type 131 (ST131) Subclone H30 as an Emergent Multidrug-Resistant Pathogen Among US Veterans

…, BL Allen, GJ Baracco, R Bedimo… - Clinical infectious …, 2013 - academic.oup.com
Background. Escherichia coli sequence type 131 (ST131), typically fluoroquinolone-resistant
(FQ-R) and/or extended-spectrum β-lactamase (ESBL)–producing, has emerged globally. …

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era

RJ Bedimo, AO Westfall, H Drechsler… - Clinical Infectious …, 2011 - academic.oup.com
(See the editorial commentary by Bozzette on pages 92–93 .) Background. Some studies
have suggested that exposure to antiretroviral therapy (ART) with abacavir is associated with …

MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in …

…, JE Mangino, D Mushatt, R Bedimo… - Clinical infectious …, 2014 - academic.oup.com
Background. Invasive candidiasis is the third most common bloodstream infection in the
intensive care unit (ICU) and is associated with morbidity and mortality. Prophylaxis and …